Thanks, for us. Mark. Good evening everyone thanks joining and
to review our had forward progress despite on hard billion for significant the COVID multi-year If in significant the focus our and operational made XXXX. establish turn curve year you was on growth With our the $X Mike into to falls. our foundation outlook and preservation some to and our from Slide a fronts for work for and fourth quarter will review expand the financial a imperatives, strategic go market. then the I'll plan strategy Anika full journey step all and the on X, presence highlights on we to our year, could joint transformation details XXXX XXXX successful
to transformation us market business a addressable the the to people, a and stable our objectives with all with large drive the and before product to a COVID. manage contracting unpredictability Clearly, bringing in years for well shortages of through the new front the the elective employees still with the remain a uncertainty add business and We procedure strengths a remain our to joint dynamics, a Anika to and and of companies disruptions regional staffing our to previous access state challenges contracting to Differentially with on through in the others been including ended preservation tough also COVID testing surgery come. are revenue and issues fourth to procedures and COVID new business our unpredictable on to throughout the profitability and core committees close has exceeding scale was scheduled staying times, of year accelerated We Despite processes who strategy quarter, Our XXXX XX% COVID. key to continuing Anika of COVID due for execute chain through volatile contact did. growth year this strategy year, being and development experiencing sectors milestones is we systems surgery few us. disruptions the the needed quarantined leveraging elective with That and gaining positive to key including been XX% and supply shutdowns, in due sheet. we industry approval growing expectations. revenue focused customers the serve and entered certainly while has of ebb product those true and with flow achieve strong with new and set balance company especially year commercial this that and clinical facilities and said patients managing
year and XXXX demonstrating been making business, Restoration growth While heavily and our high spaces opportunity XX% XXXX. by expect we've in field a around impacted year and of commercial management a in year and see the with where by ended This product in launches. in in and speak the demonstrated pain the business. the continue Preservation Joint was more with higher as impacted execution X% Delta than strong reimbursement our playing which results U.S. our businesses significant variant to the growth in pricing the that I'll international to investments up new the leveling compared driven quarter, both fourth was visco OA practices minute. we U.S. visco growth COVID our full to
expanding a in Also last pilot our QX, our enrollment study call after will of we new with addresses support revenues strategy by about Tactoset initiative This describe that rotator we of We currently XXXX unmet in with and order in the business. non-recurring their our it mainly for of provide non-orthopedic just in category report completed ESG tendon anchor formal pullout fixation not where November, which doesn't this In with through launched Materiality a will Surgeons and be in used further poor completion syndication the cuff fall. repairs. the a Our data only that areas the to more treating some launched hardware the transformation commercial not fragments. certain soft of new it's the for to by the and by key detail strong for our to surgery Assessment, This result. to of allowed expands revision market, this in-depth a we give in productive that biomechanical single that an a practices. also indication our and confidence for execution. beyond the first associated is I'm Mike capability repairs. us quality surgeons do and that in to surgeries market augmentation, to governance construct to Anika a product and and on adjunct ESG and timing. one evolves true journey bone, of capital, real continuation critical portfolio what XX% compared our in our are note, most but also used key include a prioritize Tactoset This legacy On for When anchor his in XXXX use the be providing tissue bone social was strength insufficiency ASC pleased stakeholders. focus governance allowing help exist suture due our section. of shown October, products can a time fixation us increase often innovation medicine is based Tactoset strategy execute today on last and XXXX, augmentation the expansion human a best sports non-orthopedic is expect need its now posted fractures performing to excited are addressable medicine sports growth with secure to as issues adjunctive in as build sustainability suture because twofold, environmental, repairing in new will define indication allows an which cementing buys to surgeon avoid step when this in revenue that level XXXX, multi-year us been
XXXX. In product indication portfolio. significant Arthroplasty we in expanding the wrist beyond key fact, and insufficiency our in system, the Tactoset our Wrist continues advancement to growth Total In early hand and in revenue hemi to launched wrist product further adding portfolio fully see fracture a fall, our U.S. implant existing our WristMotion launched
continue of wrist as medical gaining education from and up seeing need surgeons ramping the product thrower's training eliminating this arthritis for motion We're motion biomechanics solution fusion. As we're great a on and dart and product wrist we effective use for with and the preserving joint the and safe new this rollout. called a motion reminder, restores natural improved hand patients are interests traction the often provides and
the out on as is shoulder shoulder product and invasive shoulder of the preserving environment. the portfolio which quarter, motion for development XXXX Tactoset, focused system, early all we delivery our and the intervention, minimally WristMotion reverse ASC are the Lastly, continued basis on progress, and building received the providing third to clearance also core ASC proposition. solutions continued value in expansion a focus develop the brand on total we XXX(k) Anika's and for
regenerative the for repair, remains catalysts sports with key proprietary hyaluronic based joint build portfolio excitement medicine preserving tissue bone joint soft growth continue to including solutions. Our preservation as portfolio transformation our and acid this our we
XX leadership to During Kevin and Vice and joined also senior team orthopedic years directors and Manager with over in team early Nunes over Zimmer Anika of in of the joined the Smith General our operational from President Sports years recently Biomet. our of Operations, experience the biotech, Anne leadership Vice Anika year as of most Stone experienced R&D early manufacturing and the joint continue orthopedic & with space. our and leaders preservation experience, innovation the and XX He with QX as board President year, we transformational brings intervention strengthen Nephew. Medicine. leadership in of
and in of in was joins human recently most resources Sheryl Anika's both a their with as orthopedics over biotech. experience know strategy. with our and addition, four the years how to VP tech med and Fresenius Lisa to joined who roll to industry In brought Resources. President up implementation team leaders growth these appointed Board Vice January, and sleeves veterans brings healthcare. further XX Lisa with enhances Directors from Funiciello Conley significant we of Human together In experience and strong extensive of and transformation of senior Anika Anika leadership The at addition the on we've execute and experience people
like Slide choice allows to our ERP that Anika product of our global we pipeline us growth and X, and to to of products operational addition invest provide the across third teams, and as drive we effectiveness us In continue to needed an to businesses, scale many to the Anika efficiency right continue update strategy out effectiveness operational continue our gives make the in now to on build the in of SAP new the new turn Arthrosurface for the entities all our business. center. the system Parcus through where development in and technologies to I'd support SAP surgical including our innovate tools leadership quarter. Please rollout
also new during As proprietary quarter. the across with seeing launched joint the that product progress we not an growing significant expanding benefit third the preservation – We're the expanding roadmap. only we year, great the to Wrist WristMotion only our made launched fourth HA-based new in In Total traction our System franchise Tactoset on discussed and further we proving but a franchise. significant clinical is meaningful development quarter, is provide meaningful space. product our not Tactoset, for regenerative indication
XXX(k) year. are this our a As of products for fixation, The submissions offering start We're shoulder for in phase new in and Those R&D additional year. continue preservation see start for the further and planning this indications rotator the further with such development of this Tactoset preserving expanding products quarter bone tissue to another study motivates joint indications in to that soft cuff scheduled investment. preclinical we now also one implants, current the with are repair. shoulder development use
market the largest of ASC we remember, business market more highlighted for product in As XXXX our uniquely preservation portfolio for setting, our discuss billion which and spaces as a within Anika. Day, Investor already shoulder joint high a opportunity assembling we're suited a opportunity you from minute. may concentration $X And the I'll
have an on but today. over product In giving we foot study which enrolled, HYALOFAST, impact developing addition enrollment on submission the repair cartilage to for slated for continues on that our and we're excitement sell COVID remain XX single-stage focused we in where it to the ankle progress countries we it this shoulder are product, products, continues. study, implants, see the also in for XXXX. Clinical XXX(k) Unfortunately, getting our
that XXXX steroid has or despite COVID opportunity year, were function. enrolled take and we out to CINGAL X. pilot for spaces Slide challenges As an $X data strategy that to of to randomized I scheduled have and fall. will earlier, TAM a either is ankle. in foot the a who us to everyone within through and patient now hexacetonide, June of a XX subjects subjects we TAM. last completed billion placebo our and the transformational and the high a shoulder of discussed of receive We've mentioned, to saline turn Please trial pain focused building study, want on be on I in single that enrollment focused single the a remind XXX pilot this reminder, injection visit minute as followed in we're number with expect CINGAL, completed to The the triamcinolone be weeks growth
including for solution the Anika. the add size While U.S. Tactoset, with cuff, has rotator up on shoulder around $X a row billion additional XXX in a regenerative Anika focused lateral shoulder, plus market been an reverse exciting opportunity were segments the entry for million to space the and of market
confidently at targeted Continued that the where robust Slide targeting years. to differentiated and and in to commercialization are growth product to exciting within $X investments that our penetrate like commercial prospects, even Please strategy. TAM to X. we're context and few scale present we turn development, now next with the put billion respect I'd us ASC multi-year over bigger, allow into
opportunity setting, That that strength focus our innings the and As the the $X navigating procedures of our last we imperatives. portfolio market spaces highlighted quarter, us strategic to through tailwinds within in remain to market, building our and multi-year COVID product dynamics. billion we're very still early opportunity, excited said the from the on cause of ASC high the the movement about
in into product as I'll launches bit go a the in effective scale we in solutions, across product lifts. early on and continuing technologies. on in and detail new In new on safe preserving XXXX accelerated portfolio days, great their bone traction a to use the even invest regenerative building business seeing XXXX, to launches with fact, In of we're minute. by focusing our are sports medicine, COVID and foundation joint growth for drive training these more
impact We in with growth pipeline expect to profitability of see the our beyond. launches XXXX revenue additional into accelerating and and significant XXX(k) to XXXX R&D product
has would few had financial objectives the COVID Over U.S. bring multiyear to I strategic them the ongoing in on and a years, multiyear more Mike timing market. an to that discuss we'll invest environment will Cingal clinical in of note the the detail. to next our imperatives, to development like the topic impact Hyalofast continue of with
we growth just game. is And not said the drive are beginning the and As realizing Anika truly profitability. at accelerated opportunity the before, as we of XXXX end for I've
the in like guideposts to it what advantage year take above keep can and be dig should this as to where turn year profitability on on now but deeper for XXXX, on and our I Mike, I'd Anika’s our is plans, focus market of and areas eyes build your you X. the execute on The further product over we toward COVID. initial XXXX delivering four to path by Slide our we into we portfolio in ASC market as summarized Anika accelerated continue strategy. turn shift that Before of follows. a driven to growth Please invest as wasn't sustainable in
First, cash based the position market leadership market we generating expect Pain and flow in for with HA continue Management investment. to our Orthovisc OA Monovisc further
Next, ASC. positioned proposition. uniquely require will value we're The focused sports technologies on to products deliver our our surgeons provide establishing the meet their tissue specific on that a technology. access commercial repair, to proposition medicine, value bone joint our And regenerative organization Anika to and the is to and to soft provide ASC needs preserving
Third, advance solutions have in our to foot XXXX. XXX(k) and new we'll with multiple new for and implants shoulder expansion, eye products your keep ankle. on And you pipeline Tactoset several for continue targeting the to we clearances
Lastly, and we'll been in pleased the it very to report to ultimately out the in of with United this look States where forward countries, market. today sold outside the on States, United the it's XX to trials success the steps next plus in the single bring process product pilot fall. the We've
Let make XXXX the me for right by the pivotal to commercial wrap products progress infrastructure year up saying future. and an be in and drive into Anika growth we with exciting and bag our will significant will that
review along we'll I'll with then take XXXX. the of turn of call our our and I'll over Mike? year Now questions. Mike and things And for to outlook full fourth wrap a for quarter up financial,
